LeEco announced the acquisition of biopharmaceutical company Ajax for up to $2.3 billion in cash.

On April 27th, Eli Lilly announced that it had reached an agreement to acquire the biopharmaceutical company Ajax for up to $2.3 billion in cash, with the aim of further expanding its groundbreaking cancer therapy product portfolio. Ajax is a biopharmaceutical company dedicated to developing next-generation JAK inhibitors for patients with myeloproliferative neoplasms. The company's investigational core drug, AJ1-11095, is a novel, once-daily oral type II JAK2 inhibitor currently being evaluated in a Phase I clinical trial named AJX-101, assessing its efficacy in patients with myelofibrosis who have previously received treatment with a type I JAK2 inhibitor.